A study of depressed individuals found that an eight‐week treatment with selective serotonin reuptake inhibitors (SSRIs) ...
News Medical on MSN2d
Exploring ketamine's potential in the fight against treatment-resistant depressionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).
Antibiotics can disturb the microbiome and affect how people process emotions. This can sometimes heighten negative emotions ...
A two-part clinical trial led by University of Cincinnati researchers at the Lindner Center of HOPE is testing the use of ...
Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...
News Medical on MSN7d
Psychedelic treatments show promise for treating PTSD and depressionThe Royal Devon University Healthcare NHS Foundation Trust is leading ground-breaking clinical research that has the potential to transform treatments for neuropsychiatric disorders.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback